A new cell line from human adult bone marrow can grow infinitely and differentiate into red blood cells, making it a potential source for generating endless amounts of RBCs. This breakthrough could simplify methods for establishing immortalized cell lines and select clones with maximum RBC production potential.
Researchers have discovered the Apterous protein's crucial role in retaining memories through its interaction with the Chi cofactor and regulation of neurotransmitters. In fruit flies, Ap plays a double role in long-term memory consolidation, highlighting potential new treatment approaches for memory-related disorders.
A new study found that Omicron's immune-evading capabilities are significant, but some vaccinated and previously infected individuals have 'stronger' protection. However, the protection from Omicron may be compromised over time.
A team developed statistical models to predict the risk of early death in patients with non-intensive AML therapy. The models incorporated various health measures and quality-of-life scores, showing modest success in predicting outcomes.
A new study published in the New England Journal of Medicine found that using CAR T therapy as a second-line treatment provided better outcomes compared to standard care in patients with diffuse large B-cell lymphoma. The two-year follow-up data showed a median event-free survival of 8.3 months in the CAR T arm versus 2 months in the s...
Scientists have discovered a way to extract monthly and weekly ocean temperature records from the shells of tiny surf clams, revealing clues to Earth's past climate. The study uses a species of short-lived clam that has not been used before, allowing researchers to reconstruct sea surface temperatures and past climates with precision.
Researchers at the University of Texas MD Anderson Cancer Center demonstrated axi-cel's efficacy in treating high-risk lymphoma patients with enhanced responses and prolonged survival benefits. The study showed improved outcomes for patients with indolent non-Hodgkin lymphoma, with an estimated 81% overall survival rate at 24 months.
Researchers found a novel therapy called AVID200 safe and well-tolerated, with modest improvements in symptom burden, anemia, and spleen enlargement. The therapy needs to be combined with other drugs to optimize impact in patients.
A new study found elevated rates of a myeloma precursor condition, MGUS, in older Black adults and those with a family history of blood cancer. Individuals at high risk were twice as likely to have MGUS, an asymptomatic condition that can progress to myeloma.